Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) — Cash Flow Reinvestment Rate
Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has a Cash Flow Reinvestment Rate of 0.19x as of September 2025, reinvesting CN¥21.06 Million (capex CN¥21.06 Million ) from operating cash flow of CN¥110.78 Million. Check 600329 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Cash Flow Reinvestment Rate (2001–2024)
Historical reinvestment intensity for Tianjin Zhongxin Pharmaceutical Group Corp Ltd across 22 annual periods. Explore long-term investment intensity of Tianjin Zhongxin Pharmaceutical Group Co to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (2001–2024)
Year-by-year capital reinvestment analysis for Tianjin Zhongxin Pharmaceutical Group Corp Ltd. For live market cap and broader valuation context, see Tianjin Zhongxin Pharmaceutical Group Co stock valuation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.00x | CN¥925.65 Million | CN¥924.67 Million | CN¥117.81 Million | ▼ -2.9% |
| 2023 | 1.03x | CN¥709.84 Million | CN¥688.49 Million | CN¥140.93 Million | ▲ +481.0% |
| 2022 | 0.18x | CN¥120.18 Million | CN¥677.25 Million | CN¥107.90 Million | ▼ -69.2% |
| 2021 | 0.58x | CN¥491.87 Million | CN¥852.40 Million | CN¥156.95 Million | ▲ +68.3% |
| 2020 | 0.34x | CN¥230.21 Million | CN¥671.42 Million | CN¥189.16 Million | ▼ -44.1% |
| 2019 | 0.61x | CN¥303.67 Million | CN¥495.49 Million | CN¥205.61 Million | ▼ -62.9% |
| 2018 | 1.65x | CN¥578.87 Million | CN¥350.14 Million | CN¥175.81 Million | ▲ +239.1% |
| 2016 | 0.49x | CN¥204.73 Million | CN¥419.90 Million | CN¥116.20 Million | ▼ -61.6% |
| 2015 | 1.27x | CN¥457.26 Million | CN¥360.58 Million | CN¥92.64 Million | ▲ +418.5% |
| 2014 | 0.24x | CN¥70.15 Million | CN¥286.85 Million | CN¥70.15 Million | ▼ -27.9% |
| 2013 | 0.34x | CN¥72.42 Million | CN¥213.44 Million | CN¥72.42 Million | ▼ -82.9% |
| 2012 | 1.98x | CN¥41.18 Million | CN¥20.81 Million | CN¥41.18 Million | ▲ +699.8% |
| 2011 | 0.25x | CN¥43.02 Million | CN¥173.88 Million | CN¥43.02 Million | ▼ -50.0% |
| 2010 | 0.49x | CN¥68.79 Million | CN¥139.04 Million | CN¥68.79 Million | ▼ -52.4% |
| 2009 | 1.04x | CN¥86.74 Million | CN¥83.41 Million | CN¥86.74 Million | ▲ +322.2% |
| 2008 | 0.25x | CN¥38.36 Million | CN¥155.77 Million | CN¥38.36 Million | ▼ -90.8% |
| 2007 | 2.67x | CN¥53.74 Million | CN¥20.13 Million | CN¥53.74 Million | ▲ +366.7% |
| 2005 | 0.57x | CN¥149.80 Million | CN¥261.91 Million | CN¥149.80 Million | ▼ -97.6% |
| 2004 | 24.04x | CN¥252.31 Million | CN¥10.50 Million | CN¥252.31 Million | ▲ +212.4% |
| 2003 | 7.70x | CN¥589.20 Million | CN¥76.57 Million | CN¥589.20 Million | ▲ +700.3% |
| 2002 | 0.96x | CN¥180.40 Million | CN¥187.60 Million | CN¥180.40 Million | ▲ +13.2% |
| 2001 | 0.85x | CN¥133.95 Million | CN¥157.73 Million | CN¥133.95 Million | — |